The Carillon Mitral Contour System® is a minimally invasive device designed to reduce mitral regurgitation.

Cardiac Dimensions Announces Launch of Its Optimized U.S. Pivotal Trial – The EMPOWER Trial

“This will be the first time where we are able to study early intervention with a device in heart failure.”

Samir Kapadia, M.D.
Professor of Medicine, Cleveland Clinic

Percutaneous Mitral Valve Annuloplasty in Patients With Secondary MR and Severe LV Enlargement

“…the Carillon device improved mitral valve function, LV morphology, and functional outcome compared with patients receiving GDMT only.”

Indirect Annuloplasty of the Mitral Valve - The Carillon Mitral Contour System

The results of studies conducted to date suggest that FMR treatment with the Carillon device is both safe and effective in reducing both mitral regurgitation and left ventricular dysfunction

Cardiac Dimensions Announces Two New Meta-Analysis Publications

Both of the published meta-analyses were conducted from three prospective, core lab reviewed, CEC/DSMB adjudicated and third-party monitored clinical studies

Publication in ESC Heart Failure

Effect of Carillon Mitral Contour System on Patient Reported Outcomes in Functional Mitral Regurgitation – An Individual Participant Data Meta-Analysis

Results from the REDUCE FMR trial

Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+

Watch Gundula’s Story

Watch What Others are Saying

Klaus Witte talks about the Carillon System

Carillon Device Implantation

Kolja Sievert presents a Live Case of annuloplasty with the Carillon System

“Our patients don’t care if they have regurgitant volume when they come to the hospital. Their focus is around symptoms, quality-of-life, hospitalizations and, as the ultimate goal, long-term survival.”

Stefan Anker

Professor of Cardiology, Charité University

Effect of Carillon Mitral Contour System on Patient Reported Outcomes in Functional Mitral Regurgitation
– An Individual Participant Data Meta-Analysis

Our Offices

h

Article: Individual patient data meta‐analysis of the effects of the CARILLON® mitral contour system

Statistically significant and clinically meaningful benefits were observed in MR severity, LA and LV volumes, and rates of subsequent heart failure hospitalization

Cardiac Dimensions Announces $17.5 Million Series C Financing

The financing will be used to accelerate commercial sales of Cardiac Dimensions’ Carillon Mitral Contour System®

Australian Therapeutic Goods Administration’s Approval of the Carillon System

“This is a significant milestone as Australian patients with heart failure can now be treated earlier in their disease state with a minimally invasive treatment for mitral regurgitation.”